Zai Lab Ltd ADR ZLAB

$21.96 +0.29 (1.36%)

Valuation

Market cap
2,511,191,000
Revenue TTM
$460,160,000
Net income TTM
$-175,540,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-38.15%
Debt to equity
0.39

Trading

Volume
2,522,500
Avg volume
917,692
Day's range
$21.42 – $22.28
Shares out
113,783,000
Stochastic %K
4%
Beta
0.73
Analysts
Moderate Buy
Price target
$37.20

Price

Company profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myastheni...

Show more

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Industry
Biotechnology
Sector
Healthcare
Phone
86 21 6163 2588
Website
https://www.zailaboratory.com
Address
Building B, 899 Halei Road, Pudong, China

Latest news

Stocktwits

NVDAMillionaire Nov 2, 9:10 AM
$ZLAB Great piece that accurately captures ZLAB's current position. So if you want to refresh your understanding of ZLAB or learn about ZLAB for the first time, this is essential reading. https://everyticker.com/quote/ZLAB/analysis/zai-lab-s-global-inflection-a-china-profit-engine-funding-a-blockbuster-oncology-bet-nasdaq-zlab
0 replies
Merlintrader Oct 30, 2:29 PM
$ZLAB Q3 2026 results call: Thu Nov 5, 8:00 a.m. ET (scheduled, per company release). Chart: last close $22.36 (Oct 29). Above the 200-day SMA; below the 20-day EMA, 50-day SMA (EMA20 $23.93, SMA50 $25.02, SMA200 $20.97). RSI(14) 41. 20-day range $21.60-$26.92. Webcast: https://zailab.gcs-web.com/events/event-details/zai-lab-third-quarter-2026-financial-results/ Hub: https://www.merlintrader.com/zai-lab-stock-hub/
0 replies
Valueforall Oct 26, 8:09 PM
$ZLAB why do I keep buying the dips on red days.
0 replies
Merlintrader Oct 25, 9:41 PM
$ZLAB jumped 9.0% to $24.03, just under the 50-day EMA ($24.20) and above the 200-day ($23.05), in the middle of a 20-day range of $21.60-$26.92. Daily RSI 48. Interactive chart at JC Just Charts: https://justcharts.merlintrader.com/#ZLAB Not investment advice.
0 replies
topstockalerts Oct 23, 11:29 PM
$ZLAB this one appears to be waking up at exactly the right time.
0 replies
Valueforall Oct 23, 6:26 PM
$ZLAB I posted this here a while ago and I am sensing peak frustration. It’s a good time on this friyay to step back and do some introspection on who we really are as people. Were you a dip buyer or a pus$Y surveyor yesterday when all looked bleak and hopeless?
0 replies
DekmarTrades Oct 23, 1:00 PM
Stocks Gapping Up with Strong News this morning! $AMTD $EVAX $FXNC $ZLAB $ATEX
0 replies
OpenOutcrier Oct 23, 12:38 PM
$ZLAB (+7.2% pre) Zai Lab's zoci shows 81.8% response rate in lung cancer trial https://ooc.bz/l/118316
0 replies